P/E ratio for Eagle Pharmaceuticals (EGRX)

P/E ratio history for Eagle Pharmaceuticals from 2014 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Johnson & Johnson JNJ	11.6	718.92%	🇺🇸 USA
GlaxoSmithKline GSK	11.2	693.06%	🇬🇧 UK
Novartis NVS	29.2	1,964.61%	🇨🇭 Switzerland
Teva Pharmaceutical Industries TEVA	-8.23	-682.43%	🇮🇱 Israel
Amgen AMGN	22.1	1,463.63%	🇺🇸 USA
Eli Lilly LLY	148	10,349.31%	🇺🇸 USA
Bristol-Myers Squibb BMY	15.2	974.56%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.